11 / 36
DISTANT METASTASIS
–
FREE SURVIVAL
Dabrafenib + trametinib
100
90
80
70
60
50
40
30
20
10
0
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Months Since Randomization
Distant Metastasis–Free Survival, %
438 407 381 352 327 285 265 252 238 229 185 150 92
47
13
2
0
432 330 265 221 201 179 169 165 159 149 130 108 64
28
4
1
0
1-year, 91%
(95% CI, 88%-94%)
1-year, 70%
(95% CI, 66%-75%)
2-year, 77%
(95% CI, 73%-82%)
3-year, 71%
(95% CI, 67%-76%)
3-year, 57%
(95% CI, 52%-62%)
4-year, 67%
(95% CI, 62%-72%)
4-year, 56%
(95% CI, 51%-62%)
2-year, 60%
(95% CI, 55%-66%)
HR 0.53
(95% CI, 0.42-0.67)
No. at risk
Placebo